Tremelimumab
| Tremelimumab | |
|---|---|
| Term | Tremelimumab |
| Short definition | Tremelimumab - (pronounced) (treh-meh-LIM-yoo-mab) drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat various types of cancer. Tremelimumab is used with durvalumab to treat adults with hepatocellular carcinoma (a type of liver cancer) that cannot be surgically removed. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Tremelimumab - (pronounced) (treh-meh-LIM-yoo-mab) drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat various types of cancer. Tremelimumab is used with durvalumab to treat adults with hepatocellular carcinoma (a type of liver cancer) that cannot be surgically removed. It is also used with durvalumab and platinum chemotherapy to treat adults with non-small cell lung cancer that has spread to other parts of the body and does not have an abnormal EGFR or ALK gene. It is also being studied in the treatment of other types of cancer. Tremelimumab can block CTLA-4 and help the immune system kill cancer cells. It's a type of monoclonal antibody and a type of immune checkpoint inhibitor. Also called Imjudo
External links
- Medical encyclopedia article on Tremelimumab
- Wikipedia's article - Tremelimumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski